The fate of older diabetic patients on peritoneal dialysis: Myths and mysteries and suggestions for further research

Peritoneal Dialysis International

Volumn 27, Issue 6, 2007, Pages 611-618

  van Laecke, Steven ^a   Veys, Nic ^a   Verbeke, Francis ^a   Vanholder, Raymond ^a   van Biesen, Wim ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Diabetes; Female; Gender; Hemodialysis; Insulin resistance; Outcome; Volume status

Indexed keywords

ADIPOCYTOKINE; GLITAZONE DERIVATIVE; GLUCOSE DEGRADATION PRODUCT; HEMOGLOBIN A1C; ICODEXTRIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEPTIN; LYMPHOTOXIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

BODY COMPOSITION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; ELDERLY CARE; FLUID BALANCE; GLYCEMIC CONTROL; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; MALNUTRITION; MORTALITY; OBESITY; PATIENT EDUCATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; SELF CARE; SURVIVAL TIME; ULTRAFILTRATION; UNITED STATES; AGE; AGED; CHRONIC KIDNEY FAILURE; ELECTROLYTE BALANCE; EPIDEMIOLOGY; FEMALE; PATHOPHYSIOLOGY; PHYSIOLOGY; SEX DIFFERENCE;

AGE FACTORS; AGED; BIAS (EPIDEMIOLOGY); DIABETES COMPLICATIONS; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; OBESITY; PERITONEAL DIALYSIS; RENAL DIALYSIS; SEX FACTORS; WATER-ELECTROLYTE BALANCE;

EID: 41049096964     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080702700602     Document Type: Review

References (71)

1. Van Biesen W, Vanholder R, Verbeke F, Lameire N. Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? Perit Dial Int 2006; 26:429-34.
2. Vonesh E, Mujais S. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial 2007; 20:208-10.
3. Van Biesen W, Vanholder R, Debacquer D, De Backer G, Lameire N. Comparison of survival on CAPD and haemodialysis: statistical pitfalls. Nephrol Dial Transplant 2000; 15:307-11.
4. Burkart J, Piraino B, Kaldas H, Lee JY, Bender FH, Krediet RT. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial 2007; 20:200-2.
5. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int 2004; 66:2389-401.
6. Vonesh EF, Moran J. Mortality in end-stage renal disease: a reassessment of differences between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1999; 10:354-65.
7. Winkelmayer WC, Glynn RJ, Mittleman MA, Levin R, Pliskin JS, Avorn J. Comparing mortality of elderly patients on hemodialysis versus peritoneal dialysis: a propensity score approach. J Am Soc Nephrol 2002; 13:2353-62.
8. Collins AJ, Hao W, Xia H, Ebben JP, Everson SE, Constantini EG. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-74.
9. Locatelli F, Marcelli D, Conte F, D'Amico M, Del Vecchio L, Limido A. Survival and development of cardiovascular disease by modality of treatment in patients with end-stage renal disease. J Am Soc Nephrol 2001; 12:2411-17.
10. Heaf JG. Lokkegaard H, Madsen M. Initial survival advantage of peritoneal dialysis relative to haemodialysis. Nephrol Dial Transplant 2002; 17:112-17.
11. Schaubel DE, Morrison HI, Fenton SS. Comparing mortality rates on CAPD/ CCPD and hemodialysis. The Canadian experience: fact or fiction? Perit Dial Int 1998; 18:478-84.
12. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. Kidney Int 2007; 71:153-8.
13. Jaar BG, Coresh J, Plantinga LC, Fink NE, Klag MJ, Levey AS. Comparing the risk for death with peritoneal dialysis and hemodialysis in a national cohort of patients with chronic kidney disease. Ann Intern Med 2005; 143:174-83.
14. Stack AG, Molony DA, Rahman NS, Dosekun A, Murthy B. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int 2003; 64:1071-9.
15. Ganesh SK, Hulbert-Shearon T, Port FK, Eagle K, Stack AG. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14:415-24.
16. Snyder JJ, Foley RN, Gilbertson DT, Vonesh EF, Collins AJ. Body size and outcomes on peritoneal dialysis in the United States. Kidney Int 2003; 64:1838-44.
17. Division of Research, Kaiser Permanente. Registry Characteristics. Available from [accessed 17/7/2007]: http://www.dor.kaiser.org/studies/ diabetes/Diabetes-07.shtml
18. Schaubel DE, Blake PG, Fenton SS. Effect of renal center characteristics on mortality and technique failure on peritoneal dialysis. Kidney Int 2001; 60:1517-24.
19. Van Biesen W, Lameire NH. Residual renal function in automated peritoneal dialysis. Contrib Nephrol 1999; 129: 229-46.
20. Faller B, Lameire N. Evolution of clinical parameters and peritoneal function in a cohort of CAPD patients followed over 7 years. Nephrol Dial Transplant 1994; 9:280-6.
21. Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li SF, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15:2186-94.
22. Brown EA, Davies SJ, Rutherford P, Meeus F, Borras M, Riegel W. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14:2948-57.
23. Szeto CC, Chow KM, Leung CB, Kwan BC, Chung KY, Law MC. Increased subcutaneous insulin requirements in diabetic patients recently commenced on peritoneal dialysis. Nephrol Dial Transplant 2007; 22:1697-702.
24. Wu MS, Yu CC, Wu CH, Huang JY, Leu ML, Huang CC. Predialysis glycemic control is an independent predictor of mortality in type II diabetic patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19(Suppl 2):S179-83.
25. Ritz E, Dikow R, Morath C, Schwenger V. Salt - a potential 'uremic toxin'? Blood Purif 2006; 24:63-6.
26. Suzuki M, Kimura Y, Tsushima M, Harano Y. Association of insulin resistance with salt sensitivity and nocturnal fall of blood pressure. Hypertension 2000; 35:864-8.
27. Otsuka K, Suzuki H, Sasaki T, Ishii N, Itoh H, Saruta T. Blunted pressure natriuresis in ovariectomized Dahl-Iwai salt-sensitive rats. Hypertension 1996; 27:119-24.
28. Hu G, Jousilahti P, Peltonen M, Lindstrom J, Tuomilehto J. Urinary sodium and potassium excretion and the risk of type 2 diabetes: a prospective study in Finland. Diabetologia 2005; 48:1477-83.
29. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003; 63:1530-9.
30. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21:2549-55.
31. Gillerot G, Goffin E, Michel C, Evenepoel P, Van Biesen WV, Tintillier M. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67:2477-87.
32. Sanders PW. Salt intake, endothelial cell signaling, and progression of kidney disease. Hypertension 2004; 43: 142-6.
33. Ksiazek K, Korybalska K, Jorres A, Witowski J. Accelerated senescence of human peritoneal mesothelial cells exposed to high glucose: the role of TGF-beta1. Lab Invest 2007; 87:345-56.
34. Lee HB, Chung SH, Chu WS, Kim JK, Ha H. Peritoneal dialysis in diabetic patients. Am J Kidney Dis 2001; 38(4 Suppl 1):S200-3.
35. Ortiz A, Wieslander A, Linden T, Santamaria B, Sanz A, Justo P. 3,4-DGE is important for side effects in peritoneal dialysis what about its role in diabetes. Curr Med Chem 2006; 13:2695-702.
36. Justo P, Sanz AB, Egido J, Ortiz A. 3,4-dideoxyglucosone-3-ene induces apoptosis in renal tubular epithelial cells. Diabetes 2005; 54:2424-9.
37. Van Biesen W, Vanholder RC, Veys N, Dhondt A, Lameire NH. An evaluation of an integrative care approach for end-stage renal disease patients. J Am Soc Nephrol 2000; 11: 116-25.
38. Lee HY, Choi HY, Park HC, Seo BJ, Do JY, Yun SR. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-9.
39. Kramer HJ, Saranathan A, Luke A, Durazo-Arvizu RA, Guichan C, Hou S. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17:1453-9.
40. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16:2386-94.
41. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005; 81:543-54.
42. de Mutsert R, Snijder MB, van den Sman-de Beer, Seidell JC, Boeschoten EW, Krediet RT. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18: 967-74.
43. Stack AG, Murthy BV, Molony DA. Survival differences between peritoneal dialysis and hemodialysis among "large" ESRD patients in the United States. Kidney Int 2004; 65: 2398-408.
44. Abbott KC, Glanton CW, Trespalacios FC, Oliver DK, Ortiz MI, Agodoa LY. Body mass index, dialysis modality, and survival: analysis of the United States Renal Data System Dialysis Morbidity and Mortality Wave II study. Kidney Int 2004; 65:597-605.
45. McDonald SP, Collins JF, Johnson DW. Obesity is associated with worse peritoneal dialysis outcomes in the Australia and New Zealand patient populations. J Am Soc Nephrol 2003; 14:2894-901.
46. Ramkumar N, Pappas LM, Beddhu S. Effect of body size and body composition on survival in peritoneal dialysis patients. Perit Dial Int 2005; 25:461-9.
47. Kakiya R, Shoji T, Tsujimoto Y, Tatsumi N, Hatsuda S, Shinohara K. Body fat mass and lean mass as predictors of survival in hemodialysis patients. Kidney Int 2006; 70: 549-56.
48. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13:1307-20.
49. Johnson DW, Mudge DW, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int 2003; 23:276-83.
50. Singhal MK, Bhaskaran S, Vidgen E, Bargman JM, Vas SI, Oreopoulos DG. Rate of decline of residual renal function in patients on continuous peritoneal dialysis and factors affecting it. Perit Dial Int 2000; 20:429-38.
51. Chow KM, Szeto CC, Leung CB, Kwan BCH, Law MC, Li PKT. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int 2005; 25:374-9.
52. Axelsson J, Carrero JJ, Avesani CM, Heimburger O, Lindholm B, Stenvinkel P. Adipokine signaling in the peritoneal dialysis patient. Contrib Nephrol 2006; 150:166-73.
53. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95:136-47.
54. Rutter MK, Parise H, Benjamin EJ, Levy D, Larson MG, Meigs JB. Impact of glucose intolerance and insulin resistance on cardiac structure and function: sex-related differences in the Framingham Heart Study. Circulation 2003; 107:448-54.
55. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest 2006; 116:1793-801.
56. Lagathu C, Yvan-Charvet L, Bastard JP, Maachi M, Quignard-Boulange A, Capeau J. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49: 2162-73.
57. Stompor T, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, Zdziemicka A. An association between body mass index and markers of inflammation: is obesity the proinflammatory state in patients on peritoneal dialysis? Perit Dial Int 2003; 23:79-83.
58. Stenvinkel P, Lindholm B, Lonnqvist F, Katzarski K, Heimburger O. Increases in serum leptin levels during peritoneal dialysis are associated with inflammation and a decrease in lean body mass. J Am Soc Nephrol 2000; 11: 1303-9.
59. Diez JJ, Iglesias P, Fernandez-Reyes MJ, Aguilera A, Bajo MA, Alvarez-Fidalgo P. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf) 2005; 62:242-9.
60. Kagan A, Haran N, Leschinsky L, Shuali N, Rapoport J. Leptin in CAPD patients: serum concentrations and peritoneal loss. Nephrol Dial Transplant 1999; 14:400-5.
61. Leung JC, Chan LY, Tang SC, Chu KM, Lai KN. Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 2006; 69:2078-86.
62. Narkiewicz K, Phillips BG, Kato M, Hering D, Bieniaszewski L, Somers VK. Gender-selective interaction between aging, blood pressure, and sympathetic nerve activity. Hypertension 2005; 45:522-5.
63. Kaaja RJ, Poyhonen-Alho MK. Insulin resistance and sympathetic overactivity in women. J Hypertens 2006; 24: 131-41.
64. Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, et al. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 2001; 21:282-9.
65. Habib AN, Baird BC, Leypoldt JK, Cheung AK, Goldfarb-Rumyantzev AS. The association of lipid levels with mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2006; 21:2881-92.
66. Bredie SJ, Bosch FH, Demacker PN, Stalenhoef AF, van Leusen R. Effects of peritoneal dialysis with an overnight icodextrin dwell on parameters of glucose and lipid metabolism. Perit Dial Int 2001; 21:275-81.
67. Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21:494-8.
68. Martikainen T, Teppo AM, Gronhagen-Riska C, Ekstrand A. Benefit of glucose-free dialysis solutions on glucose and lipid metabolism in peritoneal dialysis patients. Blood Purif 2005; 23:303-10.
69. Hithaishi C, Lobbedez T, Padmanabhan S, Pineda ME, Oreopoulos DG. No beneficial effect of icodextrin on blood glucose control. Perit Dial Int 2004; 24:199-200.
70. Wong TY, Szeto CC, Chow KM, Leung CB, Lam CW, Li PK. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis 2005; 46:713-19.
71. Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. Relationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetes. Diabetes Care 2004; 27:1680-7.